ANTI-INFECTIVE DRUGS MARKET ANALYSIS

Anti-infective Drugs Market, by Drug Class Type (Anti-bacterial Drugs (B – Lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, and Others), Anti-fungal Drugs (Azoles, Echinocandins, Polyenes, and Others), and Anti-viral Drugs), by Indication Type (Pneumonia, Methicillin-resistant Staphylococcus Aureus (MRSA), Sepsis, Tuberculosis, Dermatophytosis, Aspergillosis, Candidiasis, Hepatitis Virus Infection, HIV Infection, Respiratory Virus Infection, and Others), by Route of Administration (Oral, Topical, and Parenteral), by Distribution Channel (Hospital, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2489
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Anti-infective Drugs Market: Drivers

Key players in the market are focused on new product launch, which is expected to boost the anti-infective drugs market growth. For instance, in January 2018, Melinta Therapeutics, Inc. launched its intravenous and oral formulations of Baxdela (delafloxacin) in the U.S. Baxdela is intended for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria including gram positive bacteria and gram negative bacteria.

Key players operating in the anti-infective drugs market include, Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma Inc., AstraZeneca Plc., Bayer HealthCare AG, Alkem Labs, Pacific India Pharma Limited, Pfizer, and others.

ANTI-INFECTIVE DRUGS MARKET ANALYSIS

Leading Companies

Anti-infective Drugs Market Report Snapshots

EXISTING CLIENTELE